What is heparin rebound? Exploring the parallel meanings that have existed for over 45 years

Cardiology Review

Volumn 25, Issue 5, 2008, Pages 17-20

  Koracevic, Goran P ^a  

^a Clinical Centre Nis   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LITHIUM; LOW MOLECULAR WEIGHT HEPARIN; NITRIC OXIDE; OSMOTIC AGENT; PRASUGREL; PROPRANOLOL; PROTON PUMP INHIBITOR; WARFARIN; XIMELAGATRAN;

ACCURACY; ANGINA PECTORIS; BRAIN EDEMA; BRONCHUS; DRUG EFFECT; DRUG PENETRATION; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; HYPERCHLORHYDRIA; HYPERCOAGULABILITY; HYPERTENSION; INFLAMMATION; INSOMNIA; LUNG VASCULAR RESISTANCE; MANIA; PATHOPHYSIOLOGY; PSORIASIS; REBOUND; RETINA EDEMA; REVIEW; SIDE EFFECT; STOMACH ACID SECRETION; SYMPTOM; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 48249146595     PISSN: 10926607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Bjornsson E, Abrahamsson H, Simren M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24(6):945-954.
2. Hunfeld NGM, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Systematic review. Aliment Pharmacol Ther. 2007;25(1):39-46.
3. Metz D, Inadomi J, Howden C, et al. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2007; 102(3):642-653.
4. McMullan M, Bekker J, Johengen M, et al. Inhaled nitric oxide-induced rebound pulmonary hypertension: role for endothelin-1. Am J Physiol Heart Circ Physiol. 2001; 280(2):H777-H785.
5. Namachivayam P, Theilen U, Butt W, et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med. 2006;174(9):1042-1047.
6. Young A, Newham J. Lithium in maintenance therapy for bipolar disorder. J Psychopharmacol. 2006;20(2 suppl):17-22.
7. Hancox R. Concluding remarks: can we explain the association of β-agonists with asthma mortality? A hypothesis. Clin Rev Allergy Immunol. 2006;31(2-3):279-288.
8. Levine JM. Hypertonic saline for the treatment of intracranial hypertension: worth its salt. Crit Care Med. 2006;34(12):3037-3039.
9. Sakowitz O, Stover J, Sarrafzadeh A, et al. Effects of mannitol bolus administration on intracranial pressure, cerebral extracellular metabolites, and tissue oxygenation in severely head-injured patients. J Trauma-Injury Infect Crit Care. 2007; 62(2):292-298.
10. Gillin JC, Spinweber CL, Johnson LC. Rebound insomnia: a critical review. J Clin Psychopharmacol. 1989;9(3):161-172.
11. Matsumoto Y, Freund B, Peiretti E, et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina. 2007; 27(4):426-431.
12. Gordon KB, Gottlieb A, Leonardi C, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatol Treatment. 2006;17(1):9-17.
13. Takiguchi R, Tofte S, Simpson B, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Academy Dermatol. 2007;56(2):222-227.
14. Yamauchi PS, Lowe NJ. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. J Am Acad Dermatol. 2006;54(3 suppl 2): 135-138.
15. Diaz RG, Somberg J, Freeman E, et al. Myocardial infarction after propranolol withdrawal. Am Heart J. 1974;88(2):257-258.
16. Sulfi S, Timmis AD. Ivabradine - the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Intern J Clin Pract. 2006;60(2):222-228.
17. Meinertz T, Eschenhagen T. β-receptor blockers in cardiovascular diseases. Clin Res Cardiol Suppl. 2006;1(1):43-53.
18. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12(1):10-38.
19. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol. 2006;22(1):23-45.
20. Miller RR, Olson HG, Amsterdam EA, et al. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med. 1975;293(9):416-418.
21. Hackam D, Thiruchelvam D, Redelmeier D. ACE inhibitors and aortic rupture - authors' reply. Lancet. 2006;368(9547): 1572.
22. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke. 2006;37(10):2640-2643.
23. Li JJ, Li YS, Chen J, et al. Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Med Hypotheses. 2006;66(6):1199-1204.
24. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13): 1598-1660.
25. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials - proposal of a new classification. Am J Cardiol. 2007;99(2):288-290.
26. Serebruany VL, Midei MG, Meilman H, et al. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Int J Clin Pract. 2006;60(7):863-866.
27. Carter SA, McDevitt E, Gatje BW, et al. Analysis of factors affecting the recurrence of thromboembolism off and on anticoagulant therapy. Am J Med. 1958;25(1): 43-51.
28. Dinon LR, Van der Veer JB. Recurrent myocardial infarction after cessation of anticoagulant therapy. Am Heart J. 1960; 60(1):6-22.
29. Dunn A. Perioperative management of oral anticoagulation: when and how to bridge. J Thromb Thrombolysis. 2006; 21(1):85-89.
30. Vassilopoulos P, Palcanis K. Bleeding disorders and periodontology. Review. Periodontology 2000. 2007;44(1):211-223.
31. Roth J, Margalit NS, Kesler A, et al. Perioperative brainstem infarct in a patient with antiphospholipid antibody (APLA) syndrome. Acta Neurochir (Wien). 2006; 148(10):1111-1115.
32. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin. 2006; 22(3):471-481.
33. Koracevic G. Heparin rebound phenomenon: case illustrations and practical suggestions for prevention. Haema. 2000; 3(suppl1):176-177.
34. Lauer MA, Houghtaling PL, Peterson JG, et al, for the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2001; 104(23):2772-2777.
35. Koracevic G, Andrejevic S, Sakac D. Heparin rebound phenomenon in acute coronary syndromes: advantage of low molecular weight heparins. Facta Universitatis (Med Biol). 2000;7(1):62-69.
36. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med. 2004;164(18):1961-1964.
37. Katsaridis V, Papagiannaki C, Violaris C. Embolization of acutely ruptured and unruptured wide-necked cerebral aneurysms using the neuroform2 stent without pretreatment with antiplatelets: a single center experience. Am J Neuroradiol. 2006; 27(5):1123-1128.
38. Ferretti G, Bria E, Giannarelli D, et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest. 2006;130(6):1808-1816.
39. Turpie AGG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238-1247.
40. Hull R, Pineo G, Brant R, et al, for the LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007;120(1):72-82.
41. Dent H, Lekic Z, Vicenzi M. Unfractionated heparin and coronary artery stenring. Br J Anaesth. 2006;97(4):582.
42. Koracevic G. Reader comments: acute right ventricular myocardial infarction: a very specific entity. Proc (Bayl Univ Med Cent). 2007;20(2):177-178.
43. Thadani U, Rodgers T. Side effects of using nitrates to treat angina. Expert Opin Drug Safety. 2006;5(5):667-674.
44. Noordzij P, Poldermans D, Schouten O, et al. Beta-blockers and statins are individually associated with reduced mortality in patients undergoing noncardiac, nonvascular surgery. Therapy and prevention. Coron Artery Dis. 2007;18(1):67-72.
45. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Clinical Practice Guideline. Ann Thorac Surg. 2007;83(5 suppl): S27-S86.
46. Gravlee GP, Rogers AT, Dudas LM, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology. 1992;76(3):393-401.
47. Teoh KH, Young E, Bradley CA, et al. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Circulation. 1993;88(5 pt 2):II420-II425.
48. Teoh KH, Young E, Blackall MH, et al. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg. 2004;128(2):211-219.
49. De Caterina R, Husted S, Wallentin L, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J. 2007; 28(7):880-913.
50. Kurusz M. Early techniques of extracorporeal circulation. Perfusion. 2003;18(3): 191-200.
51. Sise HS, Moschos CB, Gauthier J, et al. The risk of interrupting long-term anticoagulant treatment. A rebound hypercoagulable state following hemorrhage. Circulation. 1961;24(5):1137-1142.
52. Wright IS. A bear by the tail? The discontinuance of anticoagulant therapy. Dis Chest. 1961;40(4):454-456.
53. Marshall J. Rebound phenomena after anticoagulant therapy in cerebrovascular disease. Circulation. 1963;28(3):329-332.
54. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med. 1992;327(3):141-145.
55. Wouters KMA. Adverse events in anaesthetic practice. Br J Anaesthesia. 2006; 97(4):582-583.
56. Howard-Alpe GM, de Bono J, Hudsmith L, et al. Coronary artery stents and non-cardiac surgery. Br J Anaesthesia. 2007; 98(5):560-574.
57. Ickx B, Steib A. Perioperative management of patients receiving vitamin K antagonists. Canad J Anesthesia. 2006;53(6 suppl): S113-S122.
58. Kwon M, Kallam S, Poston R, et al. Thrombin-mediated rebound hypercoagulability after heparin withdrawal in VAD patients: a possible target for serine protease inhibition. J Heart Lung Transplant. 2006;25(2 suppl 1):148.
59. Vink R, Kamphuisen PW, van den Brink R, et al. Challenges in managing anticoagulant therapy in patients with heart valve prostheses. Expert Rev Cardiovasc Ther. 2007;5(3):563-570.
60. Sagedal S, Hartmann A, Osnes K, et al. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin. Nephrol Dialysis Transplant. 2006;21 (2):444-449.
61. Webster's New World™ Medical Dictionary. Available at: http://medical.merriam-webster.com/medical/rebound. Accessed February 20, 2008.
62. Online Medical Dictionary. Available at: http://www.cancerweb.rcl.ac.Uk/ cgi-bin/o md?rebound. Accessed April 25, 2008.
63. MedTerms.com Medical Dictionary. Available at: http://www.medterms.com/ script/ main/art.asp?articlekey=5233. Accessed February 20, 2008.
64. Dorland's Illustrated Medical Dictionary. Available at: http://www.mercksource. com/pp/us/cns/cns_hl_dorlands.jspzQzp gzEzzSzppdocszSzuszSzcommonzSzdorla ndszSzdorlandzSzdmd-a-b-000zPzhtm. Accessed February 20, 2008.